Vildagliptin – 15 years in active service with diabetologists

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents data on the vildagliptin, one of the first dipeptidyl peptidase type 4 inhibitors, which entered our clinical practice more than 15 years ago. Numerous clinical studies have proven its effectiveness in the treatment of type 2 diabetes mellitus both as monotherapy and un combination with metformin, insulin, sulfonylureas and sodium-glucose co-transporter 2 inhibitors. According to various authors, the use of vildagliptin leads to a decrease in the glycated hemoglobin level by 0.6–1.1%. In addition, body weight remains stable or decreases in most patients, which is most pronounced in combination with metformin and type 2 sodium-glucose co-transporter inhibitors.

Full Text

Restricted Access

About the authors

M. G. Pavlova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: pavlova_m_g@staff.sechenov.ru
ORCID iD: 0000-0001-6073-328X

Cand. Sci. (Med.), Associate Professor at the Department of Endocrinology № 1, Institute of Clinical Medicine n.a. N.V. Sklifosovsky

Russian Federation, Moscow

References

  1. URL: https://idf.org.
  2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М., 2023. [Algorithms of specialized medical care for patients with diabetes mellitus. Ed. by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 11th edition. M., 2023. (In Russ.)].
  3. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104–23. [Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diab Mellit. 2023;26(2):104–23. (In Russ.)]. doi: 10.14341/DM13035.
  4. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–12. [Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes in the adult population of Russia (NATION study). Diab Mellit. 2016;19(2):104–12. (In Russ.)]. doi: 10.14341/DM2004116-17.
  5. Deacon C.F., Nauck M.A., Toft-Nielsen M., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diab. 1995;44:1126–31. Doi: 10.2337/ diab.44.9.1126.
  6. Ahren B., Simonsson E., Larsson H., et al. Inhibition of dipeptidylpeptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diab Care. 2002;25:869–75. doi: 10.2337/diacare.25.5.869.6.
  7. Шестакова Е.А., Галстян Г.Р. Ингибиторы дипептидилпептидазы-4: сравнительный анализ. Проблемы эндокринологии. 2012;1:61–6. [Shestakova E.A., Galstyan G.R. Dipeptidyl peptidase-4 inhibitors: a comparative analysis. Problemy Endokrinologii. 2012;1:61–6. (In Russ.)].
  8. Инкретины: новая веха в лечении СД 2 типа. Практическое руководство для врачей. Под ред. И.И. Дедова., М.В. Шестаковой М., 2010. 92 с. [Incretins: a new milestone in the treatment of type 2 diabetes. A practical guide for physicians. Ed. by I.I. Dedov., M.V. Shestakova. M., 2010. 92 p. (In Russ.)].
  9. Lyu X., et al. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep. 2017;7:44865. doi: 10.1038/srep44865.
  10. El-Ouaghlidi A., Rehring E.R., Schweizer A., et al. The dipeptidyl peptidase IV inhibitor LAF 237 does not accentuate reactive hypoglycemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diab. 2003;52:A118.
  11. Павлова М.Г., Зилов А.В. Как избежать опасности гипогликемии – одного из важнейших осложнений терапии сахарного диабета 2-го типа? Роль ингибиторовДПП-4. Проблемы эндокринологии. 2011;57(3):48– 52. [Pavlova M.G., Zilov A.V. How to avoid the danger of hypoglycemia - one of the most important complications of the treatment of type 2 diabetes? The role of DPP-4 inhibitors. Problemy Endokrinologii. 2011;57(3):48–52 (In Russ.)].
  12. Демидова Т.Ю., Томилова Е.Н. ИДПП-4: 10 лет эффективного и безопасного управления сахарным диабетом 2 типа. Русский медицинский журнал. 2018;11(II):95–100. [Demidova T.Yu., Tomilova E.N. PID-4: 10 years of effective and safe management of type 2 diabetes. Russkii meditsinskii zhurnal=Rus Med J. 2018;11(II):95–100. (In Russ.)].
  13. Павлова М.Г., Зилов А.В. Ингибиторы дипептидил-пептидазы-4 в рутинной клинической практике – оценка эффективности и безопасности разных режимов терапии. Лечащий врач. 2012;03. [Pavlova M.G., Zilov A.V. Dipeptidylpeptidase-4 inhibitors in routine clinical practice – evaluation of the efficacy and safety of different therapy regimens. Lechashchii vrach. 2012;03. (In Russ.)].
  14. Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diab Med. 2007;24:955–61. doi: 10.1111/j.1464- 5491.2007.02191.x.
  15. Dejager S., LeBeaut A., Couturier A., Schweizer A. Sustained reduction in HbA1c during oneyear treatment with vildagliptin in patients with type 2 diabetes (T2DM). ADA. Ann Meeting. 2006;(Abstract 120-OR).
  16. Bosi E., Camisasca R.P., Collober C., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diab Care. 2007;30:890–95. doi: 10.2337/dc06-1732.
  17. Ferrannini E., Fonseca V., Zinmanet B., et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diab Obes Metab. 2009;11:157–66. doi: 10.1111/j.1463- 1326.2008.00994.x.
  18. Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diab Med. 2007;24:955–61. doi: 10.1111/j.1464- 5491.2007.02191.x.
  19. Абаева М.Ш., Нажмутдинова П.К., Аметов А.С. Влияние комбинации метформина и вилдаглиптина на показатели углеводного и жирового обменов у больных сахарным диабетом 2 типа. Фарматека. 2014;5:19–25. [Abaeva M.Sh., Nazhmutdinova P.K., Ametov A.S. Effect of a combination of metformin and vildagliptin on carbohydrate and fat metabolism in patients with type 2 diabetes mellitus. Farmateka. 2014;5:19–25. (In Russ.)].
  20. Matthews D.R., Paldanius P.M., Proot P., et al: VERIFY study group. Glycaemic Durability Of An Early Combination Therapy With Vildagliptin And Metformin Versus Sequential Metformin Monotherapy In Newly Diagnosed Type 2 Diabetes (Verify): A 5-Year, Multicentre, Randomised, Double-Blind Trial. Lancet. 2019;394(10208):1519–29. Doi: 10.1016/ S0140-6736(19)32131-2.
  21. Демидов Н.А., Анциферов М.Б., Зилов А.В. Результаты клинического исследования эффективности и безопасности фиксированной комбинации вилдаглиптин+метформин в реальной клинической практике в России (исследование мастер). Сахарный диабет. 2020;23(6):514–22. [Demidov N.A., Antsiferov M.B., Zilov A.V. Results of a clinical study of the efficacy and safety of the fixed combination vildagliptin + metformin in real clinical practice in Russia (master study). Diabetes. 2020;23(6):514–22. (In Russ.)]. doi: 10.14341/DM1250.
  22. Демидов Н.А., Котешкова О.М., Балберова М.А., Анциферов М.Б. Старт терапии сахарного диабета 2 типа с фиксированной комбинацией. Метформин с вилдаглиптином или с глибенкламидом, есть ли разница? Фарматека. 2019;14:47–53. [Demidov N.A., Koteshko- va O.M., Balberova M.A., Antsiferov M.B. Start of therapy for type 2 diabetes mellitus with a fixed combination. Metformin with vildagliptin or gliben-clamide, is there a difference? Farmateka. 2019;14:47–53. (In Russ.)]. doi: 10.18565/pharmateca.2019.14.47-53.
  23. Kusunoki Masataka, Natsume Yukie, Miyata Tetsuro, et al. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor. Drug Res. 2018;68(12):704–9. doi: 10.1055/a-0585-0145
  24. Kiran Khaladkar, Brij Mohan, Kiran Khaladkar, et al. Strong Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study. J Assoc Physic India. 2022;70(4):11–2.
  25. Subrahmanyan N.A., Koshy R.M. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. Curr Drug Saf. 2021;16(2):154–64. doi: 10.2174/1574886315999200819150544.
  26. Mannucci E., Nreu B., Montereggi C., et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(10):2745–55. doi: 10.1016/j.numecd.2021.06.002.
  27. Zannad F., Stough W.G., Lipicky R.J., et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016;2:200–5. Doi: 10.1093/ ehjcvp/pvw007.
  28. Mathieu C., Kozlovsky P., Foley J.E., et al. Clinical Safety and tolerability of vildagliptin – insights from randomised trials, observational studies and post-marketing surveillance. Eur Endocrinol. 2017;13(2):68–72. Doi: 10.17925/ EE.2017.13.02.68.
  29. McInnes G., Evans M., Del Prato S., et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diab Obes Metab. 2015;17:1085–92. doi: 10.1111/dom.12548.
  30. Wicinmski M., Gorski K., Wodkiewicz E., et al. Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. Int J Mol Sci. 2020;21(7):2275. doi: 10.3390/ijms21072275.
  31. Marfella R., Sasso F.C., Rizzo M.R., et al. ClinicalStudy Dipeptidyl Peptidase 4 Inhibition May Facilitate Healingof Chronic Foot Ulcers in Patients with Type 2 Diabetes. Hindawi Publishing Corporation Experimental. Diab Res. 2012;Article ID892706:11. doi: 10.1155/2012/892706.
  32. Vangaveti V.N., Jhamb Sh., Hayes O., et al. Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study. 2 Diab Metab Syndr. 2022;14(1):183. doi: 10.1186/s13098-022-00938-2.
  33. Lee C.H., Huang C.H., Hung K.C., et al. Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis. S J Pharmaceuticals (Basel). 2022;15(11):1358. doi: 10.3390/ph15111358.
  34. Ramadan A.E.H., Elsayed M.M.A., Elsayed A., et al. Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy. Int J Pharm X. 2024;7:100232. doi: 10.1016/j.ijpx.2024.100232.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies